In this study, berberine nanoparticles (BerNPs) were prepared using a wet-milling method with zirconium balls to enhance bioavailability and expand potential applications. The particle size and physicochemical properties of the BerNPs were analyzed using field-emission scanning electron microscopy (FE-SEM), UV–vis spectroscopy, X-ray diffraction, and Fourier-transform infrared spectroscopy. The broth dilution method was used to determine the antimicrobial activity of the BerNPs against Streptococcus mutans (S. mutans). The impact of the BerNPs on the cell surface of S. mutans was evaluated through FE-SEM analysis, focusing on its ability to inhibit biofilm formation. The results demonstrated that BerNPs were produced with an average particle size of 40–65 nm. The chemical structure of BerNPs remained consistent with that of berberine, with no modifications occurring during nanoparticle preparation. The BerNPs exhibited the ability to inhibit S. mutans, with minimum inhibitory concentration and minimum bactericidal concentration values of 78.1 and 312.5 µg/mL, respectively. BerNPs caused significant damage to S. mutans cells, disrupting the cell membrane structure, and leading to cell lysis and death. Additionally, BerNPs effectively inhibited the biofilm formation of S. mutans. In summary, BerNPs demonstrated a potent inhibitory effect on the activities of S. mutans at selectively applied concentrations.
Highly pathogenic avian influenza A/H5N1 remains a persistent threat to public health and poultry production. H5N1 antigens are typically poorly immunogenic and require effective adjuvants for antigen dose-sparing. Here, we evaluated chitosan microparticles (CSMs) and nanoparticles (CSNs) as polymeric nano-adjuvants for an H5N1 influenza vaccine, focusing on the roles of antigen dose and particle size. A purified hemagglutinin antigen was adsorbed onto chitosan particles at doses ranging from 0.15 to 5.0 µg. Both CSNs and CSMs showed consistently high loading efficiency (97–99%). BALB/c mice were immunized intramuscularly in a prime–boost schedule. Chitosan nanoparticles significantly enhanced IgG and hemagglutination inhibition (HI) titers at low antigen doses compared with aluminum hydroxide and antigen-only controls (p < 0.05). Immune responses reached saturation at a 1.5 µg dose of antigen for chitosan nanoparticles and 3.0 µg for chitosan microparticles. IgG subtype analysis suggested a balanced IgG1/IgG2a profile. Collectively, these findings support chitosan-based polymeric nanoparticles as promising adjuvants enabling dose-sparing H5N1 vaccination.